Zydus COVID-19 drug gets EUA from Indian regulator as cases spiral

23 April 2021

Indian drugmaker Zydus Cadila (NSE: CADILAHC) has received restricted emergency use approval (EUA) from the Drug Controller General of India (DCGI) for the use of Virafin (pegylated interferon alpha-2b) in treating moderate COVID-19 infection in adults.

When administered early on during COVID-19, Virafin will help patients recover faster and avoid many of the complications, the company claims.

Virafin, which has shown efficacy in Phase II and Phase III trials, will be available on the prescription of medical specialists for use in India’s hospitals, many of which are struggling to cope with the volume of COVID-19 patients. New cases currently number around 300,000 per day in the Asian country.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK